---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-093531"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2024-11-01T23:59:59+00:00"
generated_at: "2026-05-30T06:59:22.994039+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# INmune Bio Q3 net loss $12.1M; Phase 2 Alzheimer's trial fully enrolled; top-line data Q2 2025

## Summary
- Net loss $12.1M vs $8.6M Q3 2023; R&D expenses $10.1M (up from $6.0M).
- Cash and equivalents $33.6M as of Sept 30; raised $13.0M in securities purchase agreement.
- Phase 2 AD trial (XPro) fully enrolled with 201 planned patients; top-line data expected Q2 2025.
- INKmune in prostate cancer trial showed safety and NK cell activity in first cohort; highest dose cohort dosing began.
- Received $2.5M R&D rebate from Australia in July.

## SEC filing metadata
- accession: 0001213900-24-093531
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2024-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390024093531/0001213900-24-093531-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390024093531/ea0219289-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-093531
- JSON: https://secwatch.observer/filing/0001213900-24-093531.json
- Plain text: https://secwatch.observer/filing/0001213900-24-093531.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.